Skip to main content
Signal8

Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives

$REVBPress releaseNov 16, 2026, 9:00 AM ETRead the release

Revelation Biosciences announced an accelerated development plan for Gemini, replacing its original AKI program with a streamlined Phase 2a study in stage 2/3 acute kidney injury initiating in early 2027 with topline data in late 2027. The redesigned study is expected to cost approximately $7 million versus roughly $60 million under the prior plan — nearly 90% lower — and will be led by investigators at Emory Healthcare and the University of Alabama at Birmingham.

Key figures

Drug Name
Gemini (phosphorylated hexaacyl disaccharide, PHAD, TLR4 agonist)
Phase Of Trial
Phase 2a
Tam
$94 billion
Study cost new
$7 million
Topline data timing
late 2027
Cash and equivalents
$9.1 million
Study cost prior plan
$60 million
Us aki patients annually
2300000

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    REVB: Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives — AI Analysis | Signal8